Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.44 |
| ▸ | GRM4 | Q14833 | 5/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4757200 | 0.90 | FFAR2 (0.47) | FFAR2GRM4CRHBPCRHR2KDM4E | |
| SCHEMBL10114545 | 0.84 | SCN9A (0.41) | FFAR2GRM4SCN9ASMN1; SMN2NPC1 | |
| SCHEMBL4756947 | 0.83 | FFAR2 (0.47) | FFAR2GRM4CRHBPCRHR2SCN9A | |
| SCHEMBL4756645 | 0.83 | NPC1 (0.41) | FFAR2GRM4CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL4757189 | 0.79 | FFAR2 (0.48) | FFAR2GRM4SMN1; SMN2KDM4ERXFP1 | |
| SCHEMBL4757308 | 0.77 | KDM4E (0.41) | SMN1; SMN2KDM4ERXFP1NPC1RAB9A | |
| SCHEMBL4756975 | 0.77 | FFAR2 (0.48) | FFAR2GRM4CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL4756965 | 0.77 | FFAR2 (0.48) | FFAR2GRM4CRHBPCRHR2SMN1; SMN2 | |
| SCHEMBL4757157 | 0.76 | STAT3 (0.49) | FFAR2CRHBPCRHR2SMN1; SMN2KDM4E | |
| SCHEMBL10114566 | 0.76 | ALDH1A1 (0.45) | FFAR2GRM4CRHBPCRHR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895752-B2 | Alkylsulfonyl-substituted thiazolide compounds | ROMARK LABORATORIES L.C. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20120122939-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES, L.C. | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122939-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | HAVCR2, EIF2AK2, AADAC | FFAR2 4045/4885GRM4 4380/4885CRHBP 3994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.